485 ROUTE 1 SOUTH, ISELIN, NJ
Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
At The Market Offering Agreement with H.C. Wainwright for $100M
Completes Federal Dispute Resolution Meeting with FDA for ONS-5010/LYTENAVA™
Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
Outlook Therapeutics Announces Best-Efforts Public Offering of Common Stock
Supplemental Risk Factors Regarding Development and Funding Needs
Julia A. Haller, MD Steps Down from Board
Stockholder Vote Results from Annual Meeting on March 10, 2026
Q2
Q1
FY 2025
Q3
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership